Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label study of INCB057643 alone or with ruxolitinib in myelofibrosis and other advanced myeloid neoplasms
jRCT2041220002Phase 1Active, not recruiting
- Sponsor
- Incyte
- Start
- Sep 2023
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of INCB-057643 and ruxolitinib in myelofibrosis (MF), myelodysplastic syndrome (MDS), myelodysplastic/myeloproliferative neoplasm (MDS/MPN) and 1 more (2 arms), sponsored by Incyte. Primary endpoint: Number of treatment-emergent adverse events. Started Sep 2023; status: active, not recruiting.
02
Drugs
INCB-057643ruxolitinib
03
Conditions
myelofibrosis (MF)myelodysplastic syndrome (MDS)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)thrombocythemia
Beyond the preview
Go deeper on jRCT2041220002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220002.